"What the body does to the drug."
Absorption, distribution, metabolism, elimination.
Example: Propofol is rapidly distributed to the brain (fast onset) but accumulates in fat over time (slow recovery after long infusions).
"What the drug does to the body."
PK = How a car's fuel is used (tank size, speed of burning).
PD = How fast the car actually goes.
TIVA drugs enter bloodstream directly. No absorption phase means immediate availability.
Drugs move from blood to target organs. Brain receives medication quickly for rapid onset.
Liver breaks down anesthetic agents. Rate affects drug duration and recovery time.
Body removes drug metabolites. Slower clearance extends recovery, especially after long cases.
Like filling connected water tanks: drug flows quickly to small tanks (brain) but slowly accumulates in large reservoirs (fat).
The human body processes anesthetic drugs through three distinct compartments, each with different perfusion rates affecting drug distribution:
Blood and highly-perfused organs like the brain and heart.
Moderately perfused tissues like muscle.
Poorly perfused tissues like fat.
These pharmacokinetic principles determine how TIVA medications behave in your patients.
Movement of drugs from bloodstream to tissues. Determines onset speed and initial recovery time.
Rate at which the body removes drug molecules. Higher clearance means faster elimination.
Time for blood concentration to decrease by 50% after stopping infusion. Lengthens with longer administration.
Remifentanil wakes patients quickly regardless of infusion length. Propofol recovery slows significantly after extended use.
Understanding the unique properties of each TIVA agent helps anesthesiologists select optimal drugs for specific patients and procedures. The pharmacokinetic profile of each medication directly impacts induction speed, maintenance requirements, and emergence characteristics - all critical factors in tailored anesthetic delivery.
The table below summarizes key pharmacokinetic parameters for common TIVA medications:
Remifentanil's unique esterase metabolism explains its consistent half-time regardless of infusion duration. This provides predictable recovery times even after lengthy cases.
While offering rapid induction and initial recovery, propofol's context-sensitive half-time increases substantially after prolonged infusions. This can lead to delayed emergence in lengthy cases, particularly in elderly patients or those with hepatic dysfunction.
The ultra-short context-sensitive half-time makes remifentanil ideal for cases requiring rapid emergence regardless of case duration. However, this same property necessitates immediate post-operative pain management strategies to prevent analgesic gaps.
Offers intermediate properties between remifentanil and fentanyl, making it suitable for moderate-length procedures where some residual analgesia post-emergence is desirable.
The prolonged context-sensitive half-time after extended infusions can provide beneficial post-operative analgesia but may delay awakening and respiratory drive recovery in longer cases.
When combining these agents in TIVA techniques, understanding their complementary and sometimes competing pharmacokinetic profiles allows anesthesiologists to optimize induction, maintenance, and emergence characteristics for different patient populations and surgical requirements.
Understanding how pharmacokinetic principles influence clinical decisions is essential for effective TIVA administration.
Pharmacokinetics vary significantly between patients.
Time impacts drug accumulation and emergence.
PK knowledge enables precise titration.
The amount of drug present at the target tissue—usually the brain—where clinical effects actually occur.
Blood concentration (V1) ≠effect-site concentration. This difference explains the delay between drug administration and observed effects.
Think of ordering a meal: money in your wallet isn't what you eat. The food that arrives at your table is what truly matters.
Keo (pronounced "kee-oh") represents the equilibration rate between blood concentration and effect-site concentration.
Drug enters bloodstream but hasn't reached target tissue yet.
Keo mathematically describes this delay period.
Higher Keo values predict faster onset and offset of drug effects.
Understanding Keo helps predict response timing to anesthetic dose adjustments.
Faster keo means rapid drug arrival at effect site. This leads to quicker onset of anesthesia.
When infusion stops, high keo drugs clear from effect sites rapidly. This enables faster emergence from anesthesia.
Remifentanil's fast keo allows precise control during surgery. Plan your TIVA strategy around each drug's equilibration rate.

This diagram illustrates how Keo affects drug movement between the blood (plasma) compartment and the effect site (brain). The width and direction of arrows represent the rate of equilibration. Drugs with higher Keo values (like remifentanil) move more rapidly between compartments, resulting in faster onset and offset of clinical effects. Drugs with lower Keo values take longer to reach equilibrium, leading to delayed onset and prolonged duration of action after infusion stops.
Understanding how different drugs equilibrate between blood and effect site is crucial for precise TIVA administration.
Higher Keo values translate to faster equilibration between compartments, offering more predictable timing of clinical effects.
Pharmacodynamics studies how drugs affect your body at their target site. It explains what the drug does to you, unlike pharmacokinetics which describes what you do to the drug.
For TIVA practitioners, PD principles predict patient responses to anesthetic agents. This includes consciousness level, pain control, and vital sign changes.
Amount of drug at effect site
Drug attaches to specific receptors
Like pressing a car's accelerator - more pressure means more speed

Drug effects follow a predictable S-shaped curve as concentration increases at effect sites.
Starting point before drug effect begins.
Concentration producing 50% of maximum effect.
Maximum achievable effect at any dose.
Curve steepness shows sensitivity to concentration changes.
Like smartphone brightness: initial increases make big differences, but changes diminish at higher settings.
Drug effects depend on how many receptors they occupy, not simply drug concentration.
Like filling a theater - once seats are nearly full, additional audience members don't change the performance.
Propofol enhances GABA activity, producing rapid sedation and consciousness loss with a predictable onset.
Propofol features a steep dose-response curve. Small concentration increases dramatically affect anesthesia depth.
Like a sensitive dimmer switch, propofol requires careful titration to prevent oversedation.
Remifentanil acts as a potent µ-opioid receptor agonist with a shallow dose-response curve. This enables precise control of analgesia without excessive sedation effects.
Unlike propofol's steep curve, remifentanil's shallow profile allows anesthesiologists to make rapid adjustments. Pain control can be modified instantly during procedures with predictable recovery.
Despite predictive models, individual patient responses vary widely. Clinical monitoring bridges theory with actual patient needs.
Initial dose based on PD models and patient factors.
Track BIS values, vital signs, and clinical indicators.
Fine-tune infusion rates based on real-time feedback.
Maintain optimal anesthetic depth with minimal side effects.
Like adjusting music volume when entering a quiet room, TIVA requires continuous refinement based on patient responses rather than rigid protocols.
Pharmacodynamic responses vary significantly between individuals, requiring personalized approaches to TIVA.
These factors create unique PD profiles for each individual.
Two patients receiving identical propofol concentrations may experience dramatically different effects.
An elderly patient might lose consciousness at half the concentration needed for a younger patient.
PD models provide starting points, not final answers.
Continuous monitoring bridges the gap between theory and individual responses.
Individualized titration is essential for safe, effective anesthesia.
Target-Controlled Infusion (TCI) represents a sophisticated evolution in anesthetic delivery. It automatically adjusts infusion rates to maintain precise drug concentrations.
Clinician sets desired drug concentration in blood or effect site.
Computer applies Marsh (propofol) or Minto (remifentanil) models to patient data.
Pump adjusts infusion rates continuously based on predictive algorithms.
System maintains stable drug concentration at target site.
Unlike fixed-rate infusions, TCI incorporates patient factors—age, weight, height, gender—to personalize drug delivery and optimize anesthetic depth.
TCI maintains target concentrations with minimal drug level fluctuations.
Achieves rapid induction and controlled emergence from anesthesia.
Incorporates patient-specific parameters for personalized care.
TCI systems use pharmacokinetic (PK) models, such as the Marsh model for propofol or the Minto model for remifentanil, to predict drug distribution and clearance within the body. These models estimate how a drug will be absorbed, distributed, metabolized, and eliminated based on population averages and patient-specific characteristics.
Patient-specific data, including age, weight, height, and gender, are inputted into the TCI system. The system then employs complex algorithms to calculate the initial bolus dose and subsequent infusion rate required to achieve and maintain the target drug concentration in the blood or effect site.
TCI systems continuously monitor the predicted drug concentration and adjust the infusion rate in real-time to compensate for any discrepancies. This closed-loop feedback mechanism ensures that the clinical effect matches the predicted drug concentration, allowing for precise and stable control of anesthesia.
Input patient's weight, age, height, and gender into the TCI pump.
Target effect-site concentration for desired sedation level.
Pump delivers an initial bolus, rapidly achieving the target concentration.
TCI system adjusts infusion rate based on surgical stimulation and patient response.
How TIVA Works – PK/PD Basics